ANHYDROUS CRYSTALLINE FORM OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME
Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-t...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English Lithuanian |
Published |
25.01.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) are new. Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C, dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) are new, where: the anhydrous forms B-F are characterized by a X-ray diffraction powder (XRDP) having peaks at 7.3, 8.1, 9.8, 10.4, 11.1, 12.7, 13.1, 14.3, 15.4 and 15.9 +- 0.2[deg] 2theta , 4.3, 6.8, 7.4, 8.7, 10.1, 11.1, 11.9, 12.3, 12.6 and 13.1 +- 0.2[deg] 2theta , 3.9, 7.7, 7.8, 7.9, 8.6, 9.7, 10.6, 10.8, 11.1 and 12.3 +- 0.2[deg] 2theta , 7.1, 8.1, 8.9, 10.2, 10.8, 12.5, 12.7, 13.2, 13.4 and 13.9 +- 0.2[deg] 2theta and 4.4, 7.2, 8.2, 8.8, 9.6, 10.2, 10.9, 11.2, 12.1 and 12.3 +- 0.2[deg] 2theta , respectively; the ethanolate forms B, D and E are characterized by a XRDP having peaks at 7.3, 7.8, 8.8, 10.2, 12.6, 12.9, 13.4, 14.2, 14.7 et 15.1 +- 0.2[deg] 2theta , 3.8, 7.5, 7.7, 8.4, 9.4, 10.3, 10.5, 11.1, 11.5 and 11.9 +- 0.2[deg] 2theta and 7.1, 8.1, 8.8, 10.2, 10.7, 12.5, 13.2, 13.4, 13.9 and 14.2 +- 0.2[deg] 2theta , respectively; the hetero-solvate form F is characterized by XRDP having peaks at 4.4, 7.2, 8.2, 8.3, 8.8, 9.6, 10.3, 10.9, 11.2 and 12.2 +- 0.2[deg] 2theta ; the monohydrate form C is characterized by XRDP having peaks at 4.3, 6.8, 7.4, 8.6, 10.1, 11.1, 11.9, 12.2, 12.6 and 13.3 +- 0.2[deg] 2theta ; and the dihydrate form C is characterized by XRDP having peaks at 4.2, 6.9, 7.5, 8.4, 9.9, 10.9, 11.7, 12.3, 12.6 and 13.2 +- 0.2[deg] 2theta . Independent claims are included for the preparations of anhydrous forms B-F of (I). ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given. |
---|---|
AbstractList | Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) are new. Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C, dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) are new, where: the anhydrous forms B-F are characterized by a X-ray diffraction powder (XRDP) having peaks at 7.3, 8.1, 9.8, 10.4, 11.1, 12.7, 13.1, 14.3, 15.4 and 15.9 +- 0.2[deg] 2theta , 4.3, 6.8, 7.4, 8.7, 10.1, 11.1, 11.9, 12.3, 12.6 and 13.1 +- 0.2[deg] 2theta , 3.9, 7.7, 7.8, 7.9, 8.6, 9.7, 10.6, 10.8, 11.1 and 12.3 +- 0.2[deg] 2theta , 7.1, 8.1, 8.9, 10.2, 10.8, 12.5, 12.7, 13.2, 13.4 and 13.9 +- 0.2[deg] 2theta and 4.4, 7.2, 8.2, 8.8, 9.6, 10.2, 10.9, 11.2, 12.1 and 12.3 +- 0.2[deg] 2theta , respectively; the ethanolate forms B, D and E are characterized by a XRDP having peaks at 7.3, 7.8, 8.8, 10.2, 12.6, 12.9, 13.4, 14.2, 14.7 et 15.1 +- 0.2[deg] 2theta , 3.8, 7.5, 7.7, 8.4, 9.4, 10.3, 10.5, 11.1, 11.5 and 11.9 +- 0.2[deg] 2theta and 7.1, 8.1, 8.8, 10.2, 10.7, 12.5, 13.2, 13.4, 13.9 and 14.2 +- 0.2[deg] 2theta , respectively; the hetero-solvate form F is characterized by XRDP having peaks at 4.4, 7.2, 8.2, 8.3, 8.8, 9.6, 10.3, 10.9, 11.2 and 12.2 +- 0.2[deg] 2theta ; the monohydrate form C is characterized by XRDP having peaks at 4.3, 6.8, 7.4, 8.6, 10.1, 11.1, 11.9, 12.2, 12.6 and 13.3 +- 0.2[deg] 2theta ; and the dihydrate form C is characterized by XRDP having peaks at 4.2, 6.9, 7.5, 8.4, 9.9, 10.9, 11.7, 12.3, 12.6 and 13.2 +- 0.2[deg] 2theta . Independent claims are included for the preparations of anhydrous forms B-F of (I). ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given. |
Author | ELMALEH, Hagit GUILIANI, Alexandre ZASKE, Lionel DUFRAIGNE, Marielle BILLOT, Pascal MANGIN, Fabrice RORTAIS, Patricia |
Author_xml | – fullname: RORTAIS, Patricia – fullname: ZASKE, Lionel – fullname: GUILIANI, Alexandre – fullname: BILLOT, Pascal – fullname: ELMALEH, Hagit – fullname: DUFRAIGNE, Marielle – fullname: MANGIN, Fabrice |
BookMark | eNqNyksKwjAQgOEsdOHrDnMBN1HR7dBMbCCPkozQrkqRuJK0UO-PKB7A1Q8_31osyljySjTo607FcEtQxS4xWms8gQ7RQdCgjCOuQ9uBChUxtmQBvYLvVenjoInUYDT-CgkdbcXyMTznvPt1I0ATV_U-T2Of52m455JfvWUpj-fTRTIf_iBvcVcxGw |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | DIMETOKSIDOCETAKSELIO BEVANDENĖ KRISTALINĖ FORMA |
ExternalDocumentID | LT2247582TT |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_LT2247582TT3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:53:20 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English Lithuanian |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_LT2247582TT3 |
Notes | Application Number: LT09722321T |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170125&DB=EPODOC&CC=LT&NR=2247582T |
ParticipantIDs | epo_espacenet_LT2247582TT |
PublicationCentury | 2000 |
PublicationDate | 20170125 |
PublicationDateYYYYMMDD | 2017-01-25 |
PublicationDate_xml | – month: 01 year: 2017 text: 20170125 day: 25 |
PublicationDecade | 2010 |
PublicationYear | 2017 |
RelatedCompanies | Aventis Pharma S.A |
RelatedCompanies_xml | – name: Aventis Pharma S.A |
Score | 3.070561 |
Snippet | Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY |
Title | ANHYDROUS CRYSTALLINE FORM OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170125&DB=EPODOC&locale=&CC=LT&NR=2247582T |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8gGvVNUQN-pQ9mb0Q2NgYPixlrl2nYR7ZixhMpDKKJASIz_vteG6a-6Fu_crlecr37Xa9XgDsxsIRuCMQmhm20TX3ZaeMZuJRlXDsD0bX7uop3hFEvGJtPuZXX4KV6C6PqhH6q4oioUXPU91Kd15ufIBZVuZXb-9krDq0ffO5QbYeOZXFxw9Lo0GFJTGNP8zxnxLUoddBSoWds8D3YRyfalrrAnofyTcrmt0HxT-AgQVqr8hRqb2UDjrzq37UGHIa7625s7jRvewaJGwUTmsbjjHjpJOMugvCIEcRwIYl9Qh9DxoM4nxDkh3E3ZyPiRpSoUZrJdQSFnbgy-YFkbsjOgfiMe0EbWZt-S2E64tUeePcC6qv1atEEMrcLoXet3qzXL0x0bcRSIC7ErijMOfpCLWj9Sebyn7krOJbilMEGw7qGevn-sbhB81vObpXkvgAOGYLU |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLbGQIwbDBDjmQPqbWJ9rduhQl2TqkBfWjPUnabsJZDQNrEi_j5OtAEXuOUlK7bk2J_jOAC3omsL3RCITQzHaFr6vNXEM3Auy7i2usJ0OrqKd8RJOxxYj4VdVOBl-xZG1Qn9VMURUaMmqO-lOq9XP0EsqnIr13fjVxxa3gfcpdoGHcvi4oat0Z7LspSmvub7bsS1pO-ipULP2OA7sIsOtiN1gT335JuU1W-DEhzCXoa0FuURVN7KOtT87b9rddiPN9fd2Nxo3voYMi8Jh7SfDnLi94c59xCEJ4wghotJGhD6EDMepsWQ4H4Y9woWES-hRI3SXK4jKOzMk8kPJPdidgIkYNwPm7i10bcURhHf8sDNU6gulovZGZCJMxW6abfH7c7UQtdGzAXiQuyKqTVBX6gBjT_JnP8zdwO1kMfRCHl5uoADKVoZeDDsS6iW7x-zKzTF5fhaSfELXOOFxw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANHYDROUS+CRYSTALLINE+FORM+OF+DIMETHOXY+DOCETAXEL+AND+METHODS+FOR+PREPARING+SAME&rft.inventor=RORTAIS%2C+Patricia&rft.inventor=ZASKE%2C+Lionel&rft.inventor=GUILIANI%2C+Alexandre&rft.inventor=BILLOT%2C+Pascal&rft.inventor=ELMALEH%2C+Hagit&rft.inventor=DUFRAIGNE%2C+Marielle&rft.inventor=MANGIN%2C+Fabrice&rft.date=2017-01-25&rft.externalDBID=T&rft.externalDocID=LT2247582TT |